RVMD
Revolution Medicines, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Apr 19 ▲ Revolution Medicines announced updated Phase 1 data for zoldonrasib…
- Apr 21 ▲ Revolution Medicines announced updated Phase 1/2 data for daraxonras…
- Apr 21 ▲ Revolution Medicines announced that detailed results from its Phase…
- May 6 ▲ Revolution Medicines announced that Phase 1/2 data for daraxonrasib…
- May 31 ▲ Revolution Medicines reported overwhelmingly positive Phase 3 data f…
- Jul 2 FDA: Revolution Medicines Presents Phase 1/2 Clinical Data for…
- Aug 26 ▲ Revolution Medicines received FDA approval for RASONQUE (daraxonrasi…
- Sep 16 to Sep 29 ▼ 6 days of insider sells: $11.3M by 8 insiders, avg $198.57
- Oct 16 William Blair initiates
- Oct 26 ▼ 1 insider sell $431.9K at $186.99
- Nov 4 ▲ Revolution Medicines reported Q3 2026 results with RASONQUE (daraxon…
- Nov 9 to Nov 11 ▼ 2 days of insider sells: $6.9M by 2 insiders, avg $188.37
Signal stack
Where each data set points today.
- InsidersBEARISH
8 insiders sold $18.6M.
- InstitutionsBULLISH
Q3 2026: 75 added (2 new), 22 trimmed or exited. Largest new: Winslow Capital Management $260.2M.
- AnalystsBULLISH
29 of 31 rate it Buy or better. Every target is above the price.
- Short sellersSTEADY
Short interest +1.1% to 13.08M shares. 7.8 days to cover, ≈6.0% of shares.
- TrendDOWNTREND
14% below its 50-day average.
- SocialQUIET
No Reddit mentions this week. Last mention Nov 7.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| FMR LLC | ADD | $3.2B |
| Capital World Investors | ADD | $1.1B |
| JPMORGAN CHASE & CO | ADD | $973.1M |
| Assenagon Asset Management S.A. | DOUBLED | $447.7M |
| FRANKLIN TEMPLETON INC | ADD | $390.8M |
| Winslow Capital Management, LLC | NEW | $260.2M |
| DEUTSCHE BANK AG\ | ADD | $235.0M |
| Invesco Ltd. | ADD | $176.9M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
31 analystsPrice is below the lowest target. Median implies +63%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 13, 2026 | Morgan Stanley MAINTAIN | Overweight |
| Nov 6, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
| Nov 5, 2026 | TD Cowen MAINTAIN | Buy |
| Nov 5, 2026 | RBC Capital MAINTAIN | Outperform |
| Nov 5, 2026 | Piper Sandler MAINTAIN | Overweight |
| Nov 5, 2026 | Truist Securities REITERATE | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Borisy Alexis Director Nov 11, 2026 | GIFT | 10,625 sh |
Anders Jack Chief Financial Officer Nov 11, 2026 | SELL | $37.8K |
Anders Jack Chief Financial Officer Nov 11, 2026 | EXERCISE | $675.0K |
Anders Jack Chief Financial Officer Nov 11, 2026 | SELL | $633.5K |
Anders Jack Chief Financial Officer Nov 11, 2026 | SELL | $74.6K |
Anders Jack Chief Financial Officer Nov 11, 2026 | EXERCISE | $368.4K |
Anders Jack Chief Financial Officer Nov 11, 2026 | SELL | $1.1M |
Anders Jack Chief Financial Officer Nov 11, 2026 | SELL | $493.8K |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | -$0.81 | -$2.35–$0.38 | +55.9% | $462.0M |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
33 filings · 11 press releases · 5 bullish · 3 bearish · 25 neutral- NEUTRAL 144Nov 16, 2026
Stephen Kelsey, an officer of Revolution Medicines, filed a Form 144 notice to sell 108,640 shares of common stock, with an estimated aggregate market value of approximately $18.7 million. The shares are to be acquired through the exercise of stock options, and the sale is planned for execution on…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13G/ANov 16, 2026
Janus Henderson Group Ltd. filed an amended Schedule 13G disclosing a 3.5% passive stake (7,573,614 shares) in Revolution Medicines as of September 30, 2026. This is a new filing by Janus Henderson, not an amendment of a prior filing, so no prior stake comparison is available from this document.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL CLUSTERNov 13, 2026
Two insiders at Revolution Medicines sold shares in the week following Q3 earnings that showed…
The insider sales are small and pre-planned, carrying no negative signal. Monitor next quarter for RASONQUE revenue trajectory and any insider buying that would indicate conviction.
- NEUTRAL 144Nov 12, 2026
Jack Anders, an officer of Revolution Medicines, filed a Form 144 notice to sell 35,750 shares of…
This is a routine insider sale following option exercise, not a secondary offering. The dollar amount is small relative to market cap. Monitor for any pattern of repeated insider selling that could…
All RVMD filing & press-release reports (44)
- 144 reportNov 16, 2026
- SC 13G/A reportNov 16, 2026
- CLUSTER reportNov 13, 2026
- 144 reportNov 12, 2026
- SC 13G/A reportNov 5, 2026
- 8-K reportNov 4, 2026
- PRESS-RELEASE reportNov 4, 2026
- SC 13G reportOct 30, 2026
- INST-CLUSTER reportOct 23, 2026
- PRESS-RELEASE reportOct 21, 2026
- 8-K reportOct 13, 2026
- INST-CLUSTER reportOct 12, 2026
- CLUSTER reportOct 1, 2026
- CLUSTER reportSep 29, 2026
- CLUSTER reportSep 28, 2026
- CLUSTER reportSep 24, 2026
- CLUSTER reportSep 22, 2026
- CLUSTER reportSep 18, 2026
- CLUSTER reportSep 15, 2026
- 144 reportSep 15, 2026
- 144 reportSep 15, 2026
- CLUSTER reportSep 14, 2026
- 8-K reportAug 26, 2026
- PRESS-RELEASE reportAug 26, 2026
- CLUSTER reportAug 25, 2026
- 8-K reportJun 22, 2026
- PRESS-RELEASE reportJul 2, 2026
- CLUSTER reportJul 1, 2026
- 144 reportJun 15, 2026
- 144 reportJun 15, 2026
- 144 reportJun 15, 2026
- 144 reportJun 15, 2026
- 144 reportJun 11, 2026
- PRESS-RELEASE reportMay 31, 2026
- PRESS-RELEASE reportMay 6, 2026
- PRESS-RELEASE reportApr 21, 2026
- PRESS-RELEASE reportApr 21, 2026
- PRESS-RELEASE reportApr 21, 2026
- PRESS-RELEASE reportApr 19, 2026
- PRESS-RELEASE reportApr 17, 2026
- PRESS-RELEASE reportApr 15, 2026
- PRESS-RELEASE reportApr 13, 2026
- CLUSTER reportMar 19, 2026
- 8-K reportFeb 25, 2026